Mitral regurgitation in patients undergoing transcatheter aortic valve implantation for degenerated surgical aortic bioprosthesis: Insights from PARTNER 2 Valve‐in‐Valve Registry. Issue 4 (2nd March 2020)

• Record Type: Journal Article
• Authors: Murdoch, Dale J.; Sathananthan, Janarthanan; Hensey, Mark; Alu, Maria C.; Liu, Yangbo; Crowley, Aaron; Wood, David; Cheung, Anson; Ye, Jian; Feldman, Ted; Hahn, Rebecca T; Jaber, Wael A.; Mack, Michael J.; Malaisrie, S Chris; Leon, Martin B.; Webb, John G.
• Is Part Of: Catheterization and cardiovascular interventions. Volume 96:Issue 4(2020)
• Page Start: 981
• Page End: 986
• Publication Date: 2020-03-02
• Subjects: Heart -- Diseases -- Diagnosis -- Periodicals; Cardiac catheterization -- Periodicals; 616.1207572
• DOI: 10.1002/ccd.28811
• Languages: English
• ISSNs: 1522-1946

Abstract

Abstract: Background: Valve‐in‐valve (VIV) treatment with transcatheter aortic valve replacement (TAVR) is a viable option for patients with failing aortic bioprosthetic valves. Optimal management of those with concomitant mitral regurgitation (MR) remains undetermined. Therefore, we sought to assess the implications of concomitant MR in patients undergoing VIV‐TAVR. Methods and Results: The PARTNER 2 VIV registry enrolled patients with degenerated surgical aortic bioprosthesis at high risk for reoperation. Patients with core‐laboratory echocardiographic assessment of MR were analyzed; severe MR was excluded. We compared patients with ≤mild MR versus moderate MR and assessed changes in MR severity and clinical outcomes. A total of 339 patients (89 initial registry, 250 continued access) underwent VIV procedures; mean age 79.0 ± 10.2 years, mean Society of Thoracic Surgeon score 8.9 ± 4.5%. At baseline, 228/339 (67.3%) had ≤mild MR and 111/339 (32.7%) had moderate MR. In paired analysis, there was significant improvement in ≥moderate MR from baseline to 30 days (32.6% vs. 14.5%, p < .0001 [ n = 304]), and no significant change between 30 days and 1 year (13.4% vs. 12.1%, p = .56 [ n = 224]) or 1 year and 2 years (11.0% vs. 10.4%, p = .81 [ n = 182]). There was no difference in death or stroke between ≤mild MR and moderate MR at 30 days (4.0% vs. 7.2%, p = .20), 1 year (15.5% vs. 15.3%, p = .98) or 2 years (26.5% vs. 23.5%, p = .67). Conclusion: Moderate concomitant MR tends to improve with VIV‐TAVR, and was not a predictor of long‐term adverse outcomes in this cohort. In selected patients undergoing VIV‐TAVR, it may be appropriate to conservatively manage concomitant MR. Clinical Trial Registration: ClinicalTrials.gov NCT# 03225001.